Microbiotica announces the appointment of Dr Robert Tansley as Chief Medical Officer
Cambridge, UK – 10 June 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect.
Dr Tansley steps into the role at a key development stage for Microbiotica with its two lead programmes progressing through Phase 1 clinical trials in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis) with data read-outs anticipated this year.
Dr Robert Tansley commented:
I am delighted to be expanding my role at Microbiotica at this exciting time for the Company as it completes early clinical efficacy studies. Having initially joined the Board of Directors when Cambridge Innovation Capital (CIC) co-led the seed investment round in 2016, it has been a pleasure to work with such an outstanding group of academics, scientists and drug developers and to see the Company approach these key inflection points.
This is the right time for me to pursue a long-standing scientific and clinical interest in the microbiome field by taking on an executive role, while continuing to oversee my responsibilities at CIC. I’m looking forward to contributing more deeply to Microbiotica’s mission and its exciting future.
Dr Tansley will join the Company on a part-time basis as he continues his responsibilities with CIC. He will step down as a Microbiotica Board Director as he takes up this role and, in his place, Dr Anne Horgan will be appointed to the Microbiotica Board as CIC’s Investor Director.
Dr Ron Carter, who has served as consultant Chief Medical Officer will stay with the Company as Senior Vice-President, Medical Affairs and will continue to oversee the medical management of its ongoing studies.
Tim Sharpington, Microbiotica CEO, said:
We are excited that Robert is joining at this key time in the Company’s evolution. His experience as a drug developer and investor will greatly strengthen our management team as we approach key data read-outs in our first clinical trials and make plans for future growth.
